Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.7252W HIGH $27.41
Volume
208.18 K
Value Traded
4.41 M
Short % Float
15.46%
Days to Cover
6.9
-18.12%Week
-29.4%1 Month
-21.33%3 Month
-45.41%6 Month
-97.34%5 Year
-98.73%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
439.78 M
EPS (TTM)
-2.59
P/E Ratio
-
Ent. Value
268.19 M
Total Shares
37.14 M
Float Shares
30.91 M
Insiders
16.78%
Institutions
70.84%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CBIO Catalyst Timeline
Dated clinical, regulatory and corporate events for Crescent Biopharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Crescent Biopharma, Inc.
325Total events
22Upcoming
63Tier-1 (high impact)
2013 to 2034Coverage
Upcoming catalysts 2
Event history 50
▲IND ClearanceCR-002IND
FDA clears IND for CR-002 in advanced solid tumors
advanced solid tumorssource ↗
●Equity OfferingCorporate
Compensation Committee approved grant of 81,525 inducement stock options to six non-executive employees
▲Enrollment UpdateCR-001Trial
Enrollment commenced in standard of care chemotherapy combination expansion cohorts of ASCEND
multiple solid tumorssource ↗
▲Enrollment MilestoneCR-001Trial
More than 125 patients dosed in ASCEND across US, Europe and South Korea
solid tumorssource ↗
▲Dose Finding UpdateCR-001Trial
Dose escalation completed in global Phase 1/2 ASCEND trial of CR-001
solid tumorssource ↗
▲Enrollment Updatesac-TMTTrial
Phase 2 trial of sac-TMT in combination with CR-001 now enrolling participants with advanced solid tumors
advanced solid tumorssource ↗
▼Equity OfferingCorporate
Closing of underwritten public offering of ordinary shares and pre-funded warrants, including full exercise of underwriters' option
▼Equity OfferingCorporate
Crescent Biopharma announces proposed public offering of ordinary shares and pre-funded warrants
▲Trial InitiationCR-001Trial
Kelun-Biotech initiated Phase 2 trial of CR-001 in combination with sac-TMT in China
NSCLCsource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
●Poster PresentationCR-001Presentation
Trial in progress poster of ASCEND study design presented at ASCO 2026
solid tumorssource ↗
●IND SubmissionCR-002IND
IND application for CR-002 to be submitted to FDA in mid-2026
solid tumorssource ↗
◆Poster PresentationCR-001Presentation
Trial in Progress Poster Presentation at ASCO 2026
solid tumorssource ↗
◆Poster PresentationCR-001Presentation
Trial in progress abstract of ASCEND study design accepted for poster presentation at ASCO 2026
solid tumorssource ↗
▲IND ClearanceCR-001IND
Kelun-Biotech received IND approval from NMPA for CR-001 (SKB118)
advanced solid tumorssource ↗
▲Trial InitiationCR-001Trial
Kelun-Biotech commenced Phase 1/2 monotherapy trial of CR-001 in China
advanced solid tumorssource ↗
◆Topline ReadoutCR-001Clinical Data
Interim PoC data expected for CR-001
NSCLC, other solid tumorssource ↗
▲Trial InitiationCR-001Trial
ASCEND Phase 1/2 global clinical trial underway to evaluate CR-001 in advanced solid tumors
advanced solid tumorssource ↗
▲First Patient DosedCR-001Trial
First patient dosed in ASCEND Phase 1/2 trial of CR-001
advanced solid tumorssource ↗
◆Oral PresentationPresentation
Fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026
◆Trial InitiationCR-001Trial
Kelun-Biotech plans to initiate Phase 1/2 trial of CR-001 (SKB118) in China
solid tumorssource ↗
◆Trial InitiationSKB105Trial
SKB105 Phase 1/2 monotherapy clinical trial anticipated to commence
solid tumorssource ↗
▲First Patient DosedCR-001Trial
First patient dosed in global Phase 1 trial for CR-001
solid tumorssource ↗
▲Trial InitiationCR-003Trial
Initiation of Phase 1/2 trial of CR-003 (SKB105) in Greater China
solid tumorssource ↗
▲Partnership / LicenseCorporate
Exclusive partnership with Kelun-Biotech for CR-001 and SKB105 (CR-003)
solid tumorssource ↗
●Oral PresentationPresentation
Conference call and webcast to discuss partnership and pipeline
▲Partnership / LicenseCorporate
Strategic collaboration with Kelun-Biotech announced in December 2025
●Poster PresentationCR-001Presentation
Preclinical data for CR-001 presented at SITC 2025
solid tumorssource ↗
◆Oral PresentationCR-001Presentation
Preclinical data for CR-001 presented at SITC
solid tumorssource ↗
◆Oral PresentationPresentation
Morgan Stanley 23rd Annual Global Healthcare Conference fireside chat
Past FDA Catalysts and PDUFA Decisions
How CBIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | CR-002 | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 82%
Micro Cap(rank 538 of 656)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CR-001 Small moleculeNCT07335497 | Locally Advanced / Metastatic Solid Tumors | Phase 1 | RECRUITING | 290 | Feb 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every CBIO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| uproleselan | acute myeloid leukemia | Phase 2/3 | 2024-10-29 | did not show a statistically significant improvement in event free survival (EFS) for patients receiving uproleselan in combination with 7+3 chemotherapy versus chemotherapy aloneRead More | GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint ROCKVILLE, Md.--(BUSINESS WIRE)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Brumm Joshua TDirector, Officer (Chief Executive Officer) | Sell | -7,837 271,765 held | $16.71 | 09/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CBIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 1.3 % (-18.8 %) | 49.48 M | 2.75 M |
CBIO Institutional Ownership Trends
CBIO Short Interest
Shares sold short, counted twice a month.
15.46%
Short % of Float
of tradable shares sold short
4.8M
Shares Sold Short
+40.2% vs prior count
6.9 High
Days to Cover
trading days of normal volume to buy every short share back
697.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CBIO ranks across every disease it competes in
Competitive Position is a premium feature
See how CBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCBIO News
CBIO▼ -5.1%on this news
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Crescent Biopharma has announced significant progress in its clinical pipeline, particularly with the CR-001 bispecific antibody in the ASCEND trial, which is enrolling patients for combination therapies. Initial monotherapy data is expected in Q1 2027, with further combination studies planned. The company aims to initiate Phase 3 trials by early 2028, reflecting a robust development strategy in oncology.
Read more →CBIOCrescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma announced the approval of options to purchase 81,525 shares as inducement awards for six non-executive employees. This decision, made by the Compensation Committee, aims to enhance recruitment efforts under the 2025 Employment Inducement Incentive Award Plan. The options have a 10-year term and an exercise price of $13.94, with a structured vesting schedule.
Read more →CBIOCrescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Crescent Biopharma has received FDA clearance for its IND application for CR-002, a PD-L1-targeted topoisomerase inhibitor ADC. The Phase 1/2 APOLLO trial will evaluate CR-002 in various solid tumors, including NSCLC and HNSCC, with patient enrollment expected to start in Q4 2026. Initial clinical data is anticipated in late 2027.
Read more →CBIO▲ +10%on this news
Crescent Biopharma to Present at September Investor Conferences
Crescent Biopharma, a clinical-stage biotechnology firm, announced its participation in two upcoming investor conferences in September 2026. The company will present at the Cantor Global Healthcare Conference on September 10 and the Morgan Stanley Global Healthcare Conference on September 14. Live webcasts of these events will be available on their website.
Read more →CBIOCrescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma reported its second quarter 2026 financial results, highlighting progress in its clinical trials, particularly for CR-001 in the ASCEND Phase 1/2 trial. The company has also initiated a Phase 2 trial in China for CR-001 in combination with sacituzumab tirumotecan. Additionally, Crescent completed a public offering, enhancing its financial position and extending its cash runway into 2028.
Read more →CBIOCrescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Crescent Biopharma has completed its public offering of 9,387,896 ordinary shares, raising about $143.7 million. The offering included a full exercise of the underwriters' option to purchase additional shares. The shares were sold at $14.50 each, and the company aims to leverage the funds to advance its oncology pipeline.
Read more →CBIOCrescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Crescent Biopharma has announced the pricing of its public offering, which includes 8,094,793 ordinary shares and pre-funded warrants. The shares are priced at $14.50 each, with gross proceeds estimated at $125 million. The offering is set to close on July 16, 2026, pending customary closing conditions. Jefferies and other firms are managing the offering.
Read more →CBIOCrescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Crescent Biopharma has announced a proposed public offering of ordinary shares and pre-funded warrants. The offering is intended to support the company's development of cancer therapies and includes a 30-day option for underwriters to purchase additional shares. The completion of the offering is subject to market conditions and other factors.
Read more →CBIO▲ +5.7%on this news
Crescent Biopharma to Present at June 2026 Investor Conferences
Crescent Biopharma, a clinical-stage biotechnology firm, will present at several investor conferences in June 2026. The company focuses on developing advanced therapies for cancer, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates. Live webcasts of the presentations will be available on their website.
Read more →CBIO▼ -13.8%on this newsshared move
Crescent Biopharma to Present at June Investor Conferences
Crescent Biopharma, a clinical-stage biotechnology company, announced its participation in two investor conferences in June 2026. The presentations will take place at the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference. Live webcasts will be available, showcasing the company's commitment to advancing cancer therapies.
Read more →CBIOCrescent Biopharma Announces Grants of Inducement Awards - May 29, 2026
Crescent Biopharma announced the approval of equity inducement awards for two non-executive employees, granting options to purchase 16,950 shares. The options, with a 10-year term and an exercise price of $21.47, are part of the company's strategy to attract and retain talent. This move aligns with Crescent's commitment to advancing cancer therapies.
Read more →CBIOCrescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Crescent Biopharma announced the presentation of a trial in progress for its ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, at the 2026 ASCO Annual Meeting. The Phase 1/2 trial is evaluating CR-001 in various solid tumors, with enrollment ongoing. Initial data readouts are anticipated in early 2027, aiming to assess the drug's safety and preliminary antitumor activity.
Read more →CBIO▲ +6.2%on this news
Crescent Biopharma Announces Grants of Inducement Awards - May 12, 2026
Crescent Biopharma, a clinical-stage biotechnology company, announced the approval of equity inducement awards for five non-executive employees. The awards consist of options to purchase 129,075 shares at an exercise price of $18.52, with a 10-year term. This move is part of the company's strategy to attract talent and advance its oncology pipeline.
Read more →About Crescent Biopharma, Inc.
Headquarters300 FIFTH AVENUE, WALTHAM, MA, 02451
BIOPHARMAWATCH ELITE PLUS
Trade the next CBIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime